Skip to main content
. 2017 Aug 30;3(3):00019-2016. doi: 10.1183/23120541.00019-2016

TABLE 1.

Patient characteristics (n=75)

First time point Second time point 6month change pvalue#
Age years 69.9±8.7
Male 64 (85.3%)
Current/previous/never smoker 7 (9.3%)/62 (82.7%)/6 (8.0%)
Biopsy-proven 16 (21.3%)
Treated with pirfenidone 11 (14.7%) 27 (36.0%)
Treated with CS and/or IS 13 (17.3%) 15 (20.0%)
FVC % predicted 87.5±20.4 86.3±22.3 −1.2±0.8 0.21
DLCO % predicted 43.5±11.1+ 41.1±13.2+ −2.4±0.8 <0.01
CPI 47.4±10.7+ 49.2±13.0+ 1.7±0.7 0.03
Serum KL-6 U·mL−1 1121±733 1251±889 131±63 0.06
Serum SP-D ng·mL−1 302±224 308±240 7±18 0.71

Data are presented as mean±sd unless otherwise stated. CS: corticosteroid; IS: immunosuppressive agent; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; CPI: composite physiologic index. #: comparisons between the first and second time points using the Wilcoxon matched-pairs signed-ranks test; KL-6: Krebs von den Lungen-6; SP-D: surfactant protein-D. : n=57, a subject was included if FVC data were available at both time points; +: n=56, a subject was included if DLCO and CPI data were available at both time points.